The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Resveratrol Inhibits HCoV-229E and SARS-CoV-2 Coronavirus Replication In Vitro
Open accessAbstract
A novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in China at the end of 2019 causing a large global outbreak. As treatments are of the utmost importance, drug repurposing embodies a rich and rapid drug discovery landscape, where candidate drug compounds could be identified and optimized. To this end, we tested seven compounds for their ability to reduce replication of human coronavirus (HCoV)-229E, another member of the coronavirus family. Among these seven drugs tested, four of them, namely rapamycin, disulfiram, loperamide and valproic acid, were highly cytotoxic and did not warrant further testing. In contrast, we observed a reduction of the viral titer by 80% with resveratrol (50% effective concentration (EC50) = 4.6 µM) and lopinavir/ritonavir (EC50 = 8.8 µM) and by 60% with chloroquine (EC50 = 5 µM) with very limited cytotoxicity. Among these three drugs, resveratrol was less cytotoxic (cytotoxic concentration 50 (CC50) = 210 µM) than lopinavir/ritonavir (CC50 = 102 µM) and chloroquine (CC50 = 67 µM). Thus, among the seven drugs tested against HCoV-229E, resveratrol demonstrated the optimal antiviral response with low cytotoxicity with a selectivity index (SI) of 45.65. Similarly, among the three drugs with an anti-HCoV-229E activity, namely lopinavir/ritonavir, chloroquine and resveratrol, only the latter showed a reduction of the viral titer on SARS-CoV-2 with reduced cytotoxicity. This opens the door to further evaluation to fight Covid-19.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing
Gordon, D. E., Jang, G. M., Bouhaddou, M., Xu, J., Obernier, K., White, K. M., O’Meara, M. J., Rezelj, V. V., Guo, J. Z., Swaney, D. L., et al. (2020) · Nature · doi:10.1038/s41586-020-2286-9 · Cited by 4,405 · cited 3×
“The cytotoxicity we observed for lopinavir/ritonavir and chloroquine in the present study is in line with these previous reports [48,49].”
BackgroundResultSARS-CoV-2 vaccines in development
Krammer, F. (2020) · Nature · doi:10.1038/s41586-020-2798-3 · Cited by 2,098 · cited 1×
“Despite the fact that SARS‐CoV‐2 vaccines have been quickly developed [8], no definitive therapy has been shown to be effective to date against SARS‐CoV‐2 and therefore new treatments are actively needed [9].”
BackgroundThe pivotal link between ACE2 deficiency and SARS-CoV-2 infection
Verdecchia, P., Cavallini, C., Spanevello, A., & Angeli, F. (2020) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2020.04.037 · Cited by 1,237 · cited 2×
“Increase in the ACE2/Ang1-7/MasR axis has been reported to reduce hyperinflammation in Covid-19 patients [44].”
BackgroundIdentification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs
Jeon, S., Ko, M., Lee, J., Choi, I., Byun, S. Y., Park, S., Shum, D., & Kim, S. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00819-20 · Cited by 675 · cited 1×
“The mTOR inhibitor rapamycin, a drug used as an immunosuppressant in transplant patients, was reported to reduce MERS‐CoV infection by over 60% in vitro [17] by suppressing viral protein expression and virion release [18].”
BackgroundEffects of Resveratrol on the Renin-Angiotensin System in the Aging Kidney
Jang, I.-A., Kim, E. N., Lim, J. H., Kim, M. Y., Ban, T. H., Yoon, H. E., Park, C. W., Chang, Y. S., & Choi, B. S. (2018) · Nutrients · doi:10.3390/nu10111741 · Cited by 110
Cited by
Tkaczenko, H., & Kurhaluk, N. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031098 · Cited by 80
Coronaviruses spike glycoprotein endodomains: The sequence and structure‐based comprehensive study
Kumar, P., Bhardwaj, A., Mukherjee, B., Joshi, R., & Giri, R. (2023) · Protein Science · doi:10.1002/pro.4804 · Cited by 2
Enhancement of mRNA translation efficiency through 5’-UTR engineering
Broset, E., Blasco-Machín, I., Lampaya, V., Matute, C., Toro-Córdova, A., & Martínez-Oliván, J. (2025) · doi:10.1101/2025.09.30.679448
eIFiso4G editing confers high and broad-spectrum resistance against rice yellow mottle virus
Auguy, F., Chéron, S., Dossou, L., Pinel-Galzi, A., Thomas, E., Aribi, J., Celli, M. G., Cunnac, S., Hébrard, E., & Albar, L. (2026) · Peer Community Journal · doi:10.24072/pcjournal.740
Metadata
- Authors
- Pasquereau, S., Nehme, Z., Haidar Ahmad, S., Daouad, F., Van Assche, J., Wallet, C., Schwartz, C., Rohr, O., Morot-Bizot, S., & Herbein, G.
- Venue
- Viruses
- Publisher
- MDPI AG
- Published
- 2021-02-23
- Volume
- 13
- Issue
- 2
- Pages
- 354
- ISSN
- 1999-4915 (ISSN-L)
- OpenAlex
- W3131475711
- Cited by
- 175
- References
- 5
- FWCI
- 10.81
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Resveratrol Inhibits HCoV-229E and SARS-CoV-2 Coronavirus Replication In Vitro. https://app.cochat.ai/papers/10.3390/v13020354
- The paper
- Pasquereau, S., Nehme, Z., Haidar Ahmad, S., Daouad, F., Van Assche, J., Wallet, C., Schwartz, C., Rohr, O., Morot-Bizot, S., & Herbein, G. (2021). Resveratrol Inhibits HCoV-229E and SARS-CoV-2 Coronavirus Replication In Vitro. Viruses. https://doi.org/10.3390/v13020354
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.